Added benefits and user satisfaction with a low-dose oral contraceptive containing drospirenone: Results of three multicentre trials

Clinical Drug Investigation

Volumn 29, Issue 2, 2009, Pages 73-78

  Bitzer, Johannes ^a   Paoletti, Anna M ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Ethinylestradiol drospirenone, therapeutic use; Fixed combinations; Oral contraceptives, therapeutic use

Indexed keywords

DESOGESTREL PLUS ETHINYLESTRADIOL; DROSPIRENONE PLUS ETHINYLESTRADIOL; ORAL CONTRACEPTIVE AGENT; UNCLASSIFIED DRUG; YASMINELLE;

CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LOW DRUG DOSE; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; REVIEW; WELLBEING; WITHDRAWAL BLEEDING;

ANDROSTENES; CONTRACEPTIVES, ORAL, COMBINED; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; ESTROGEN REPLACEMENT THERAPY; ETHINYL ESTRADIOL; FEMALE; HUMANS; MULTICENTER STUDIES AS TOPIC; PATIENT COMPLIANCE; PATIENT SATISFACTION; QUALITY OF LIFE; QUESTIONNAIRES; WOMEN'S HEALTH;

EID: 58149377673     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/0044011-200929020-00001     Document Type: Review

References (29)

1. Borgelt-Hansen L. Oral contraceptives: an update on health benefits and risks. J Am Pharm Assoc (Wash) 2001; 41 (6): 875-86
2. Boschitsch E, Skarabis H, Wuttke W, et al. The acceptability of a novel oral contraceptive containing drospirenone and its effect on well-being. Eur J Contracept Reprod Health Care 2000; 5 Suppl. 3: 34-40
3. Brown C, Ling F, Wan J. A new monophasic oral contraceptive containing drospirenone: effect on perimenstrual symptoms. J Reprod Med 2002; 47 (1): 14-22
4. Thorneycroft IH, Gollnick H, Schellschmidt I. Superiority of a combined oral contraceptive containing drospirenone to a tri-phasic preparation containing norgestimate in acne treatment. Cutis 2004; 74 (2): 123-30
5. Pearlstein TB, Bachmann GA, Zacur HA, et al. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 2005; 72 (6): 414-21
6. Yonkers KA, Brown C, Pearlstein TB, et al. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 2005; 106 (3): 492-501
7. Rosenberg MJ, Waugh MS, Long S. Unintended pregnancies and use, misuse and discontinuation of oral contraceptives. J Reprod Med 1995; 40 (5): 355-60
8. Thorneycroft IH. Yasmin: the reason why. Eur J Contracept Reprod Health Care 2002; 7 Suppl. 3: 13-8
9. Skouby SO. Contraceptive use and behavior in the 21st century: a comprehensive study across five European countries. Eur J Contracept Reprod Health Care 2004; 9 (2): 57-68
10. Foidart J-M, Wuttke W, Bouw GM, et al. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care 2000; 5 (2): 124-34
11. Huber J, Foidart JM, Wuttke W, et al. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care 2000; 5 (1): 25-34
12. Cibula D, Karck U, Weidenhammer HG, et al. Efficacy and safety of a low-dose 21-day combined oral contraceptive containing ethinylestradiol 20μg and drospirenone 3mg. Clin Drug Invest 2006; 26 (3): 143-50
13. Fuhrmann U, Krattenmacher R, Slater EP, et al. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contra-ception 1996; 54 (4): 243-51
14. Muhn P, Krattenmacher R, Beier S, et al. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Pharmacological characterization in animal models. Contraception 1995; 51 (2): 99-110
15. Parsey KS, Pong A. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception 2000; 61 (2): 105-11
16. Bachmann G, Sulak PJ, Sampson-Landers C, et al. Efficacy and safety of a low-dose 24-day combined oral contraceptive con-taining 20 micrograms ethinylestradiol and 3mg drospirenone. Contraception 2004; 70 (3): 91-8
17. Gruber DM, Huber JC, Benedetto Melis G, et al. A comparison of the cycle control, safety, and efficacy profile of a 21-day regimen of ethinylestradiol 20μg and drospirenone 3mg with a 21-day regimen of ethinylestradiol 20μg and desogestrel 150μg. Treat Endocrinol 2006; 5 (2): 115-21
18. Kluft C, Endrikat J, Mulder SM, et al. A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 microg ethinylestradiol and a reference containing desogestrel and 30 microg ethinyl estradiol. Contraception 2006; 73 (4): 336-43
19. Endrikat J, Dusterberg B, Ruebig A, et al. Comparison of efficacy, cycle control, and tolerability of two low-dose oral contraceptives in a multicenter clinical study. Contraception 1999; 60 (5): 269-74
20. Endrikat J, Hite R, Bannemerschult R, et al. Multicenter, comparative study of cycle control, efficacy and tolerability of two low-dose oral contraceptives containing 20μg ethinylestradiol/100μg levonorgestrel and 20μg ethinylestradiol/500μg norethisterone. Contraception 2001; 64 (1): 3-10
21. Mishell Jr DR, Guillebaud J, Westhoff C, et al. Combined hormonal contraceptive trials: variable data collection and bleeding assessment methodologies influence study outcomes and physician perception. Contraception 2007; 75 (1): 4-10
22. Archer DF, Maheux R, DelConte A, et al. A new low-dose monophasic combination oral contraceptive (Alesse) with levonorgestrel 100 micrograms and ethinyl estradiol 20 micrograms. North American Levonorgestrel Study Group (NALSG). Contraception 1997; 55 (3): 139-44
23. Fruzzetti F, Lello S, Lazzarini V, et al. The oral contraceptive containing 30 microg of ethinylestradiol plus 3mg of drospirenone is able to antagonize the increase of extracellular water occurring in healthy young women during the luteal phase of the menstrual cycle: an observational study. Contraception 2007; 75 (3): 199-203
24. Endrikat J, Jaques MA, Mayerhofer M, et al. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 microof grams gestodene and 20 micrograms ethinylestradiol/150 micrograms desogestrel, with respect to efficacy, cycle control, and tolerance. Contraception 1995; 52 (4): 229-35
25. Fuchs N, Prinz H, Koch U. Attitudes to current oral contraceptive use and future developments: the women's perspective. Eur J Contracept Reprod Health Care 1996; 1 (3): 275-84
26. Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol 1998; 179 (3 Pt 1): 577-82
27. Wiegratz I, Lee JH, Kutschera E, et al. Effect of four oral contraceptives on hemostatic parameters. Contraception 2004; 70 (2): 97-106
28. Apter D, Borsos A, Baumgartner W, et al. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. Eur J Contracept Reprod Health Care 2003; 8 (1): 37-51
29. Paoletti AM, Lello S, Fratta S, et al. Psychological effect of the oral contraceptive formulation containing 3mg of drospirenone plus 30 microg of ethinyl estradiol. Fertil Steril 2004; 81 (3): 645-51